Eli Lilly Warns Tirzepatide-B12 Mix in Compounded Drugs May Pose Safety Risks [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Eli Lilly ( NYSE:LLY ) has raised new safety concerns around compounded versions of its weight-loss medicine Zepbound, warning that the drug's active ingredient, tirzepatide, could pose potential risks when combined with vitamin B12 in products sold by US compounders. In an open letter released Thursday, the company said testing of compounded formulations identified significant levels of an impurity caused by a chemical reaction between tirzepatide and the vitamin. Lilly cautioned that such reactions could potentially lead to toxicity or immune responses in patients receiving the mixture. Warning! GuruFocus has detected 4 Warning Sign with LLY. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company said people obtaining tirzepatide-B12 products from compounders, telehealth providers, or medical spas may be exposed to medicines with uncertain safety profiles. According to Lilly, additional testing also detected
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.MarketBeat
- Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]Fortune
- Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/6/26 - Form PRE
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website